Citations

Clear

2429 citation(s) found for "Shah, SS".

Reduced overall survival in TP53-mutated ccus is driven by prior cytotoxic exposure and cytopenia rather than leukemic progression
Tessier, Steven , Jabban, Yazan Khair Eldien , Patnaik, Mrinal M. , Ongie, Laura , Mangaonkar, Abhishek A. , Gangat, Naseema , Foran, James M. , Punwani, Nathan , Kusne, Yael , Begna, Kebede, Tefferi, Ayalew , Al‐Kali, Aref , Jabban, Yazan, Alkhateeb, Hassan B. , Hogan, William J. , Saliba, Antoine N. , Badar, Talha , Murthy, Hemant S. , Yi, Cecilia Arana , Hiwase, Devendra , Shah, Meera

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 5643-5643

10.1182/blood-2025-5643 Get It

Abstract Background: TP53-mutated (TP53mut) myeloid neoplasms (MN) are a biologically and clinically distinct subgroup of blood cancers associated with extremely poor outcomes and limited response to conventional therapies. In some patients, MN are preceded by clonal cytopenia of undetermined significance (CCUS). Prior cytotoxic exposure (treatment related, TR) is an independent predictor for survival in CCUS (Li et al, Blood Adv. 2024). As TP53mut CCUS and MN are enriched in TR cases, the interaction between cytotoxic exposure and TP53mut status on the risk of progression and survival remains unclear. Methods: Adult patients with CCUS who were evaluated at the Mayo Clinic or South Australian myelodysplastic syndrome (MDS) Registry (Adelaide, Australia) were included. CCUS and MDS were defined according to the 5th edition of the WHO classification for MN (Khoury et al, 2022), except for the exclusion of cases harboring MDS-defining cytogenetics. Next-generation sequencing was performed using a targeted panel covering genes commonly mutated in MN. In cases with >1 TP53mut, VAFs were summed. Survival outcomes were assessed by Kaplan-Meier with log-rank testing. Univariate and multivariate analyses were estimated using Cox proportional hazards regression. Results: Of 320 CCUS cases, 50 (15.6%) harbored TP53mut (TP53mut CCUS), whereas 270 (84.4%) were wild-type (TP53wt CCUS). Median age at diagnosis was 71 years (range 16-99). TP53mut CCUS had a greater proportion of females (60% vs 33.7%, p<0.001) and TR (66% vs 23%, p<0.001) compared to TP53wt. Hematologic parameters including hemoglobin, red cell distribution width, mean corpuscular volume, white blood count, absolute neutrophil count, platelets, and bone marrow blasts were comparable between the two groups. Almost all TP53mut (n=48, 96%) were located in the DNA-binding domain and the median variant allele frequency (VAF) was 9% (range 2-46%). Five (10%) cases harbored 2 TP53mut. The distribution of TP53mut VAF among patients was as follows: ≤2.5% (n=2), 2.5-5% (n=10), 5-10% (n=19), 10-20% (n=11), and ≥20% (n=7). The proportion of cases with cytogenetic abnormalities was smaller in TP53mut compared to TP53wt CCUS(12% vs 25.9%, p=0.035). Both cohorts had a comparable median number of mutations: 2 (range 0-7) in TP53mut and 2 (range 0-5) in TP53wt. The most common co-mutations in TP53mut CCUS were TET2 (n=8, 17.8%), PPMD1 (n=7, 15.6%), DNMT3A (n=6, 13.3%), ASXL1 (n=6, 13.3%), and SRSF2 (n=4, 8.9%). At last follow up, the rate of progression was comparable between TP53mut and TP53wt CCUS (12% vs 22%, p=0.13). Median time to MN progression was not reached in TP53mut and 6.25 months in TP53wt CCUS (p=0.5197). A significantly higher proportion of TP53mut cases acquired complex cytogenetics compared to TP53wt cases (33% vs 2%, p=0.024) at MN progression. Of 20 deaths observed in the TP53mut cohort, non-myeloid hematologic malignancies (n=6, 30%), infections (n=5, 25%), and TP53mut MN (n=4, 20%) were the 3 most common causes. With a median follow-up of 4 years (IQR 1.2-4.8), median OS was longer in de novo (dn) cases (8.7 years for dn TP53wt; not reached for dn TP53mut) and shorter in TR cases (3.3 years for TR TP53wt; 4.8 years for TR TP53mut). Notably, TP53mut showed no independent prognostic impact in the entire cohort, or when stratified by TR vs dn CCUS. On multivariate analysis that included TP53mut status, factors independently associated with inferior OS included prior therapy (HR 2.21, 95% CI 1.41-3.45, p<0.001), anemia (HR 4.1, 95% CI 1.88-8.99, p<0.001), and thrombocytopenia (HR 2.38, 95% CI 1.43-3.95, p<0.001). Similarly, TR CCUS (HR 1.6, 95% CI 1.06-2.4, p=0.03) and anemia (HR 2.15, 95% CI 1.25-3.7, p=0.006) were independently associated with inferior progression free survival. Conclusion: TP53 mut in CCUS did not independently predict inferior survival or increase leukemic transformation. While TP53mut CCUS were less likely to harbor cytogenetic abnormalities at diagnosis, significantly more cases harbored genomic instability at leukemic transformation. The poor outcomes attributed to TP53mut CCUS were driven by prior cytotoxic exposure, cytopenia – particularly anemia, and non-leukemic causes of death. These findings suggest risk stratification in CCUS should prioritize clinical context over TP53mut status alone.
Blast clearance dynamics and time to response across IDH1- and IDH2-mutated AML
Najeeb, Mohamad Sheikh, Alkabbani, Oudai, He, Rong , Matin, Aasiya , Mangaonkar, Abhishek A. , Patnaik, Mrinal M. , Gangat, Naseema , Litzow, Mark R. , Yi, Cecilia Y. Arana , Foran, James M. , Begna, Kebede, Al‐Kali, Aref , Jevremović, Dragan , Greipp, Patricia T. , Hefazi, Mehrdad , Hogan, William J. , Yi, Cecilia Arana , Shah, Meera , Alkhateeb, Hassan B. , Kewan, Tariq Zuheir , Saliba, Antoine N.

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 7045-7045

10.1182/blood-2025-7045 Get It

Abstract Background: Isocitrate dehydrogenase (IDH) mutations are frequently implicated in the development of acute myeloid leukemia (AML). In a recent study (Salman MY, Blood Adv 2025), it was reported that IDH2 mutation subtypes, R140 and R172, may respond differently to intensive chemotherapy. In this study, we evaluated mid-cycle and end-of-cycle bone marrow blast responses in AML patients with IDH2 R140, IDH2 R172, and IDH1 R132 mutations, aiming to determine whether these subtypes exhibit different response dynamics. Methods: We reviewed the charts of AML patients diagnosed at Mayo Clinic, Rochester, between the years 2016 - 2023 that had available next generation sequencing (NGS) data. Institutional review board approval was obtained. All data were recorded at the time of AML diagnosis. Patients without molecular data or not treated with intensive chemotherapy (7+3 or CPX-351) were excluded from this study. Bone marrow blast percentages were assessed at mid-induction (days 14-21) and end of cycle (counts recovery). Blast clearance dynamics and complete remission rates were compared across IDH mutation subgroups and correlated with outcomes. GraphPad Prism 10.0.0 was used for statistical analysis. Results: Out of 381 AML patients, 31 had IDH2 mutations (23 with R140 and 8 with R172), and 8 had IDH1 mutations (all R132). Among patients with IDH2 mutations, those with R172 had numerically higher median mid-cycle bone marrow blast percentage compared to R140 (10% vs. 4%, p = 0.37). There was no significant difference in mid-cycle blast percentages between patients with IDH1 and IDH2 mutations (4.5% vs. 4%, p = 0.8). At mid-cycle, 68% of patients with IDH2 R140 had blast counts <5%, compared to 38% of those with IDH2 R172, suggesting a trend for faster mid-cycle clearance in the R140 group, though not statistically significant (OR 3.57, p = 0.2). In a broader comparison, 60% of IDH2-mutated patients and 50% of IDH1-mutated patients achieved blast clearance (blasts <5%) at mid-cycle, though not statistically significant (p = 0.7). At the end of the induction, patients with IDH2 R140 had significantly lower median bone marrow blast percentages compared to those with R172mutations (2% vs. 4%, p = 0.01). Similarly, patients with IDH1 mutations showed low blast counts compared to the IDH2 group (1.5% vs. 3%, p = 0.1). A higher proportion of IDH2 R140 patients achieved blast clearance compared to those with R172 mutations (100% vs. 75%, p = 0.06), while proportion of patients who achieved blast clearance were similar between IDH1 and IDH2 patients (87.5% vs 93.1%, P = 0.5). Analysis of overall complete remission rates (including both complete remission [CR] and CR with incomplete hematologic recovery [CRi]) within the IDH2-mutated group showed a higher rate in patients with the R140 mutation compared to those with R172 (87% vs. 75%), though the difference was not statistically significant (p = 0.5). When comparing IDH1- and IDH2-mutated patients, overall complete remission rates were 75% and 84%, respectively, with no significant difference observed (p = 0.6). Kaplan–Meier analysis of time to end-of-induction blast clearance revealed no statistically significant difference between IDH2 R140 and R172 patients (median time to clearance: 31 vs. 37 days, p = 0.3). Similarly, no difference was observed between IDH1 and IDH2-mutated patients (33 vs. 31 days, p = 0.9). Overall survival analyses showed no significant difference between IDH2 R140 and R172 groups (median 66.8 months vs not reached, P = 0.4). Likewise, no difference was observed between IDH1 and IDH2 patients (44.4 months vs not reached, P = 0.7), indicating similar overall survival across mutation subtypes. Conclusion: IDH2-R140 was associated with more effective blast cytoreduction following intensive induction compared to IDH2-R172. Although not statistically significant, IDH2 R172consistently showed trends toward higher blast percentages, delayed response, and lower overall complete remission rates. These findings align with the recent study reporting significantly slower blast reduction and delayed response in R172-mutated AML. Also, no significant differences were found between IDH1- and IDH2-mutated patients in terms of response kinetics or overall survival. Together, these findings highlight potential biological differences among IDH mutation subtypes that may impact treatment response and require further investigation in larger prospective cohorts.
Clinicopathologic features of myeloid neoplasms and pre-neoplasms with isolated ZRSR2 mutations
Oskarsdottir, Alma, He, Rong , Jiang, Jennifer , Yacout, Mahmoud, Viswanatha, David S., Craig, Fiona E. , Kelemen, Katalin, Al‐Kali, Aref , Greipp, Patricia T. , Shah, Meera , Alkhateeb, Hassan B. , Jevremović, Dragan

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 7394-7394

10.1182/blood-2025-7394 Get It

Abstract Introduction: The ZRSR2 gene, located at Xp22.2, encodes a protein component of the RNA spliceosome. Alterations in ZRSR2 have been reported in various myeloid neoplasms (MN) and their precursors. They are frequently accompanied by other co-mutations, most commonly TET2. Isolated ZRSR2 mutations, however, are less commonly encountered and their clinicopathologic features have not been well documented. Aim: To describe the clinicopathologic features of MN and their precursors with isolated ZRSR2 mutations. Methods: Next-generation sequencing (NGS) was performed on peripheral blood (PB) or bone marrow (BM) samples from patients with confirmed/suspected MN using a 35-47 gene MN-targeting NGS panel. MN and clonal cytopenia of undetermined significance (CCUS) cases with isolated likely pathogenic/pathogenic (LP/P) ZRSR2 mutations were identified. Pathology diagnoses were rendered following the 2022 WHO/ICC classification and the slides were reviewed by three pathologists. Electronic medical records were reviewed for collection of relevant laboratory data. This study was approved by our institution's Institutional Review Board. Results: Of 164 ZRSR2-mutated cases, 10 cases with isolated LP/P mutations in ZRSR2 were identified. Patients were all male, with a median age 69.5 years. Three patients were diagnosed with CCUS, five with myelodysplastic syndrome (MDS), one with chronic myelomonocytic leukemia (CMML, MDS/MPN) and one with mixed phenotype acute leukemia (MPAL). Six patients had additional variants of undetermined significance (VUS) detected in ASXL1, CALR, EZH2, IDH2 and TET2. The other four patients had no additional variants identified by NGS but had cytogenetic abnormalities. One patient with MPAL had MECOM and IGH gene rearrangements detected on cytogenetic analysis. All patients had macrocytic anemia. One CMML patient with accompanying VUS in TET2 also had absolute monocytosis. BM cellularity and erythroid and granulocytic morphology were variable, ranging from unremarkable to left-shifted and dysplastic morphology. Nine (90%) cases showed atypical megakaryocyte morphology, characterized by hypolobated forms and osteoclast-like forms with separated and eccentrically located nuclear lobes. Interestingly, this megakaryocytic morphology was also observed in CCUS cases, albeit with lower frequency, below the 10% threshold necessary for the diagnosis of MDS. Megakaryocyte distribution was normal. Conclusions: Isolated LP/P ZSRS2 mutations are seen in a spectrum of myeloid neoplasms, including CCUS. They show a strong association with macrocytic anemia and megakaryocytic atypia/dysplasia. The presence of additional cytogenetic alterations and variants of undetermined significance is a confounding factor in determining the role of ZRSR2 mutations in driving the pathogenesis and morphologic features of these diseases.
30 years of classical hematology drugs in the US: Approvals, costs, and sales
Go, Lewis T , Go, Lucas T, Elliott, Michelle A. , Padrnos, Leslie , Pruthi, Rajiv K. , Rivera, Candido E., Rouse, Rachelle, Shaikh, Marwan , Wysokinska, Ewa , Abeykoon, Jithma P. , Godby, Richard , Jensen, Chelsee , Shah, Surbhi , Siddiqui, Mustaqeem , Sridharan, Meera , Wolanskyj, Alexandra P. , Go, Ronald S.

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 2604-2604

10.1182/blood-2025-2604 Get It

Abstract Background: In 2022, Medicare alone spent $42.1 billion on prescription drugs, with antineoplastic and classical hematology drugs accounting for 44% and 8% of the total, respectively (2024 MedPAC Data Book). While antineoplastic drugs have been extensively studied, classical hematology drugs have received comparatively little attention. We analyzed US Food and Drug Administration (FDA) approvals of classical hematology drugs over the past 30 years and examined their per-patient costs and annual total US sales. Methods: We identified all classical hematology drugs (those prescribed by hematologist/oncologists for non-malignant indications) approved by the FDA from January 1, 1995 to December 31, 2024, including novel pharmaceuticals (synthesized from chemical compounds), biologics (derived from living organisms), and biosimilars (highly similar, but not identical, to biologics previously approved). Cost estimates for 2024 were based on wholesale acquisition costs (WAC), using annual WAC for continuous-duration treatments and typical course WAC for fixed-duration treatments. WAC and US gross sales data for 2024 were obtained from IPD Analytics (Aventura, FL). Results: A total of 98 classical hematology drugs were approved over the past 30 years—11% in 1995–2004, 26% in 2005–2014, and 63% in 2015–2024. These included pharmaceuticals (36%), biologics (54%), and biosimilars (10%). Six gene therapies received approval: 3 for hemophilia and 1 each for sickle disease, beta thalassemia, and sickle cell disease/beta thalassemia (dual indication). Common categories of indications included bleeding (31%), anemia (30%), neutropenia (9%), and thrombocytopenia (9%). Leading diagnoses were hemophilia (25%), chemotherapy-induced neutropenia (9%), thromboembolism (8%), paroxysmal nocturnal hemoglobinuria (PNH; 7%), anemia of chronic kidney disease (6%), iron deficiency anemia (6%), and immune thrombocytopenia (5%). The median cost for gene therapies was $2.9 million per treatment (range: $2.2 million–$3.5 million). Among non-gene therapies, median costs were $3,000 per course for fixed-duration treatments (range: $64–$378,000) and $467,000 annually for continuous-duration treatments (range: $2,400–$1.8 million). The most expensive fixed-duration treatments targeted hemophagocytic lymphohistiocytosis ($378,000/8-week course), while the most expensive continuous-duration treatments were for hemophilia (median: $630,000/year; range: $270,000–$853,000). Estimated 2024 US gross sales across all drugs exceeded $70 billion. Top-selling indications included thromboembolism ($43.5 billion), hemophilia ($6.9 billion), immune thrombocytopenia ($4.9 billion), PNH ($4.7 billion), chemotherapy-induced neutropenia ($2.8 billion), anemia of chronic kidney disease ($2.0 billion), and iron deficiency anemia ($1.8 billion). Total sales for all gene therapies combined were $143 million. Six drugs have been discontinued (year approved/year discontinued/reason): betrixaban (2017/2020/business), daprodustat (2023/2024/business), fidanacogene elaparvovec (2024/2025/business), oprelvekin (1997/2011/business), peginesatide (2012/2013/safety), and voxelotor (2019/2024/safety). There are limitations to our study. Some drugs have non-classical hematology indications (anticoagulants in atrial fibrillation; luspatercept in myelodysplastic neoplasm) and/or may also be prescribed by non-classical hematologists (erythropoiesis stimulating agents by nephrologists and medical oncologists). We were unable to disaggregate the sales data in these situations. Therefore, the annual sales for certain indications may be overestimated. Conclusions: Classical hematology drugs contribute substantially to US prescription drug spending, with over $70 billion in annual sales and medications for thromboembolism accounting for over half of the costs. Approvals have accelerated over the past three decades, doubling each decade. Biologics and biosimilars now represent two-thirds of approvals. Continuous-duration treatments, particularly for rare hereditary diseases like hemophilia, carry significant financial burden, with annual costs per patient often exceeding $0.5 million. In these conditions, if gene therapies demonstrate durable efficacy, they may prove to be cost-effective alternatives. As more gene therapies are developed, evaluating their long-term value relative to chronic high-cost treatments will be essential for shaping future reimbursement and access strategies.
Trends in mortality and comorbidity of type 2 diabetes mellitus among u.S. adultswith multiple myeloma: A CDC wonder-based analysis, 1999–2023
Wazir, Hakim, Shaikh, Aqsa, Cherukuri, Swathi, Dasaradhan, Thejaswi, Shah, Khushbakht, Javed, Rumman, Reza, I M Khalid, Amjad, Amna, Nawaz, Shaheen, Inam, Noora, Ramzan, Shah E, Tummala, Nayanika, Fernandes, Bolivia, Wazir, Hakim, Shaikh, Aqsa, Cherukuri, Swathi, Dasaradhan, Thejaswi, Shah, Khushbakht, Javed, Rumman, Imankhah, Reza , Amjad, Amna, Nawaz, Shaheen, Inam, Noora, Ramzan, Shah E, Tummala, Nayanika, Fernandes, Bolivia

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 8115-8115

10.1182/blood-2025-8115 Get It

Abstract Background : Type 2 diabetes and Multiple myeloma are becoming a growing cause of worry among aging populations. Type 2 diabetes and Multiple myeloma share many risk factors like age, obesity, and chronic inflammation. It is also found that diabetes may influence the worsening of multiple myeloma. Hence it becomes crucial to understand the epidemiological intersections between the two conditions in order to optimise treatment and lower death rates. This study assesses the trends in mortality in patients with Type 2 diabetes and Multiple myeloma in the United States from 1999-2023. Methods : We analyzed death certificates of adults aged>45 years' from the CDC-WONDER database with Type 2 diabetes (ICD-10 codes: E10-14) and Multiple myeloma (ICD-10 codes: C90) from 1999-2023. Age-adjusted mortality rates (AAMR) per 100,000 population were stratified by gender, race, census region, year and age. Join-Point analysis was performed to estimate annual percent change (APC) and average annual percent change (AAPC) in mortality trends, along with 95% confidence intervals (CIs). Results: Between 1999 and 2023, Type 2 diabetes and Multiple myeloma caused 22,467 deaths in patients aged>45 years. The overall AAMR increased from 0.647 in 1999 to 0.886 in 2023. Demographically, AAMR among the men increased significantly from 0.827 to 1.205 (AAPC: 1.22; 95% CI: -1.02 to 3.52). Although experiencing a lower mortality as compared to males, females also experienced a surge in mortality from 0.563 to 0.633(AAPC: 0.90; 95% CI: -0.11 to 1.93). In terms of race, mortality increased among the Non-Hispanic (NH) Black or African Americans from 1.942 to 2.158 (AAPC:0.60 ; 95% CI: -0.06 to 1.26), moreover the AAMR in the Hispanics increased from 0.986 to 1.099 (AAPC: 0.84; 95% CI:-0.05 to 1.73) while those among the white community increased from 0.493 to 0.679 (AAPC: 0.87; 95% CI -1.13 to 2.91). Geographically, regions in the South showed the highest overall AAMR (0.760) followed by the West (0.748), followed by the Midwest(0.731), and the Northeast (0.617). Between the urban and rural areas, rural areas had a higher AAMR as compared to the urban areas with an overall AAMR of 0.809. When stratified according to states, AAMRs varied highly from the highest in Columbia to the lowest in California. Conclusion: The overall mortality rates for Type 2 diabetes and Multiple myeloma increased between the years 1999-2023. The greatest change was seen in males, regions in the Northeast, racially in NH Blacks and the rural areas.
Disparate post-relapse survival outcomes by race/ethnicity for children with B-cell acute lymphoblastic leukemia: An analysis from the recall-1 study
Berry, Abigale, Elgarten, Caitlin W. , Liu, Hongyan , Lind, Katherine , Nguyen, Gabriella, Quigg, Troy C. , Bhojwani, Deepa, Shah, Nirali, Maude, Shannon L. , Zarnegar‐Lumley, Sara , Weisnicht, Allison , Thornock, Molly, Thomas, Stéphanie , Tastet, Nicholas, Symons, Heather J. , Shoag, Jamie , Saraf, Amanda J. , Rahrig, April , Prosser-Dombrowski, Alexandra, Patel, Hiren P. , Murphy, Megan , Murphy, Lindsey , Moore‐Higgs, Giselle J., Milner, Jordan , Lee‐Miller, Cathy , Kohorst, Mira A. , Kinoshita, Hannah , Krieger, Elizabeth , Vasanna, Smitha Hosahalli, Hinson, Ashley , Hammoud, Miza Salim, Hamill, Darcy, Goode, Erin , Faulk, Kelly , Vasco, Alejandra Escobar, Elo, Lyannette, Elias, Anna , Eom, Elizabeth, Drinkwine, Jennifer, Davis, Laurie , Chu, Roland, Briscoe, Eliza, Bhatla, Deepika, Beck, Jill C., Al-Mulla, Abdulla , Ahmed, Ibrahim , Li, Yimei , Zheng, Daniel J. , Fabrizio, Vanessa A , Ortega, Maria, Rubinstein, Jeremy , Hall, Anurekha G. , Bhojwani, Deepa , Shah, Nirali N , Toner, Keri , Tastet, Nicholas, Rahim, Mahvish Qureshi , Prosser-Dombrowski, Alexandra, Pfeiffer, Thomas , Murphy, Megan, Moskop, Amy , McNerney, Kevin Owen , Hoover, Alex , Dolan, J. Gregory , Briscoe, Eliza, Winestone, Lena E. , Myers, Regina M.

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 4525-4525

10.1182/blood-2025-4525 Get It

Abstract Introduction Pronounced disparities in pediatric B-lymphoblastic leukemia (B-ALL) outcomes by race and ethnicity persist in the contemporary era. Gaps in overall survival (OS) from initial diagnosis are wider than event-free survival, suggesting that post-relapse mechanisms may contribute. However, data on treatment and outcomes after relapse are lacking. In a large, multicenter, real-world cohort of children and young adults with high-risk 1st relapse of B-ALL, we sought to (1) define survival outcomes by race/ethnicity and (2) explore if differences in therapy utilization drive outcomes. Methods We conducted an analysis within the Retrospective Study of Contemporary Approaches to 1st Relapse in B-ALL (ReCALL-1) cohort, which includes patients <30 years who initiated 1st relapse therapy between 2018-2022. This analysis was restricted to patients treated at US centers for “high-risk” 1st relapse, defined as relapse for which hematopoietic cell transplant (HCT) is generally standard-of-care: Early relapse (medullary <36m; isolated extramedullary <18m), late relapse with persistent end of reinduction disease, Ph+ B-ALL or age ≥18 years. Patients with Trisomy 21, those who received cell therapy before relapse and those who died during reinduction were excluded. The primary exposure was race/ethnicity categorized as Hispanic, non-Hispanic Black (NHB), non-Hispanic White (NHW), and other/unknown. The primary outcome was OS from relapse. Multivariable Cox regression models were constructed to include other social drivers of health (SDOH; health insurance, preferred language) and disease characteristics. Results Of 479 patients in ReCALL-1, 311 from 31 centers met inclusion for this analysis (41% Hispanic, 7% NHB, 46% NHW, 5% NH-other/unknown). With a median follow-up of 47m, OS differed by race/ethnicity (log-rank p=0.017): Hispanic, 4y OS 59%; NHB, 37%; NHW, 68%. Compared to NHW patients, NHB patients had an increased hazard of death (HR 2.3, 95% CI 1.3-4.3, p=0.006), while Hispanic patients were more similar to NHW patients (HR 1.3, 95% CI 0.9-2.0, p=0.16). Adjustment for SDOH only marginally attenuated the risk for NHB patients (aHR 2.0, 95% CI, 1.1-3.7, p=0.031) and led to equivalent outcomes for Hispanic patients (aHR 0.9, 95% CI, 0.5-1.5, p=0.66). Adjusting for disease characteristics that differed by race/ethnicity at p<0.2 (time to relapse, Ph+, Ph-like, KMT2Ar, age ≥18, or relapsed infant ALL) did not diminish the risk for NHB patients (aHR 2.0, 95% CI, 1.1-3.7, p=0.032) while outcomes remained equivalent for Hispanic patients (aHR 1.2, 95% CI, 0.8-1.8, p=0.40). Point estimates of cumulative incidence of non-relapse mortality (NRM) were highest in NHB patients (Hispanic, 4y NRM 13%, NHB 22%, NHW 11%), but this trend was not statistically significant (Gray’s p=0.52). Only 17% of patients initiated therapy for relapse on a clinical trial with no differences observed by race/ethnicity. Most patients received definitive treatment for relapse with either CAR T cell therapy (CART) or HCT: 79% overall, 74% Hispanic, 91% NHB, and 83% NHW. CART and HCT were utilized equally (39% and 40%, respectively) and the proportion that received each therapy did not vary by race/ethnicity. Time to CART/HCT, external referral for treatment, receipt of investigational v commercial CART, and use of post-CART consolidative HCT revealed no differences by race/ethnicity. Of the 66 patients (21%) who did not receive cell therapy, 26 had planned for CART or HCT, but did not receive due to disease progression or NRM (n=24; 12 Hispanic, 10 NHW), or insurance barriers (n=2, both Hispanic). After HCT, OS was worse for NHB patients (log-rank p=0.03) with 4y OS of 42% v 85% for NHW and 75% for Hispanic. Post-CART, 4y OS was 40% for NHB v 59% for NHW and 51% for Hispanic, but this difference was not statistically significant. Conclusion In a large real-world cohort of children with high-risk 1st relapse of B-ALL, we found a two-fold increased hazard of death for NHB patients compared to NHW patients, even after adjustment for other SDOH factors and high-risk disease features. In contrast to previous studies of adult patients, children appeared to have equal access to cell therapies across races/ethnicities. We found that Hispanic patients, who comprised >40% of the cohort, had similar survival to NHW children, suggesting that availability of cellular and immunotherapies may be mitigating historically observed disparities for children with relapsed B-ALL.
Long-term progression-free survival benefit with ciltacabtagene autoleucel in standard-risk relapsed / refractory multiple myeloma
Costa, Luciano da Fontoura , Manier, Salomon , Voorhees, Peter M. , Lin, Yi, Htut, Myo , Ho, Phoebe Joy, Shah, Urvi, Zhao, Man , Balogh, Ágnes , Li, Katherine , Slaughter, Ana, Benachour, Nina, Lonardi, Carolina, Sun, Huabin, Lendvai, Nikoletta , Lengil, Tamar, Patel, Nitin , Koneru, Mythili, Florendo, Erika, Costa, Octavio, Mahajan, Vrinda, Strouse, Christopher , Stewart, Keith, Sidana, Surbhi , Sidana, Surbhi , Strouse, Christopher S , Costa, Luciano, Oriol, Albert , Dytfeld, Dominik , Roeloffzen, Wilfried W. H. , Li, Quanlin , Ghosh, Arnab , Rodríguez‐Otero, Paula

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 94-94

10.1182/blood-2025-94 Get It

Abstract Introduction: The CARTITUDE-4 study (NCT04181827), which enrolled patients with lenalidomide-refractory multiple myeloma (MM) after 1–3 prior lines of therapy (pLOT), demonstrated a significant benefit of ciltacabtagene autoleucel (cilta-cel) over established triplet regimens. However, the benefit of cilta-cel for patients with standard-risk cytogenetics remains less defined. Here, we report outcomes in patients with standard-risk cytogenetics from the intent-to-treat and as-treated populations in CARTITUDE-4. Methods: InCARTITUDE-4, patients randomized to the cilta-cel arm underwent apheresis and bridging treatment with either pomalidomide, bortezomib, and dexamethasone (PVd) or daratumumab, pomalidomide, and dexamethasone (DPd), followed by lymphodepletion therapy with cyclophosphamide and fludarabine, and then a single cilta-cel infusion. Progression-free survival (PFS) was assessed using a validated computerized algorithm. The intent-to-treat population included 208 patients; 32 patients progressed or died on bridging therapy, resulting in an as-treated population of 176 patients. Patients with high-risk cytogenetics, defined as del(17p), t(14;16), t(4;14), gain/amp(1q) (n=105), or with unknown cytogenetics (n=12), were excluded from the as-treated analysis. The 12-month minimal residual disease (MRD)-negative complete response (CR) was defined per the International Myeloma Working Group criteria as the proportion of participants with CR or better prior to and at 12 months (±3 months), achieving MRD-negative status at 12 months (+3 months) after cilta-cel infusion, as determined by next-generation sequencing (10-5), prior to progressive disease or subsequent anti-myeloma therapy. For the as-treated population, PFS rates were measured from the time of cilta-cel infusion. Results: In CARTITUDE-4, in the intent-to-treat population, at a median follow-up of 33.6 months, patients with standard-risk cytogenetics had a 30-month PFS rate (95% CI) of 71.0% (58.8–80.2) in the cilta-cel arm (N=69) vs 43.2% (31.3–54.5) in the standard-of-care (SOC) arm (N=70). Patients with standard-risk cytogenetics in the as-treated population (n=59) had a 30-month PFS rate of 80.5% (95% CI, 67.2–88.8). In CARTITUDE-1 (NCT03548207), which evaluated cilta-cel in patients with heavily pretreated relapsed/refractory MM (RRMM; ≥3 pLOT), the 30-month PFS rate among patients with standard-risk cytogenetics (negative for del(17p), t(14;16), or t(4;14); n=68) was 59.9% (95% CI, 47.2–70.5). In the CARTITUDE-4 as-treated population with standard-risk cytogenetics, 8 PFS events occurred within 1 year and 4 PFS events beyond 1 year of cilta-cel infusion. Twenty-six patients achieved MRD-negative CR at 12 months after cilta-cel; 100.0% of these patients were progression free at 30 months. Fourteen patients were not evaluable for MRD due to: calibration failure (n=12), no sample availability for testing (n=1), or indeterminate results post baseline (n=1). Conclusions: The PFS rate at 2.5 years for patients with standard-risk RRMM was higher in CARTITUDE-4 compared with CARTITUDE-1, supporting the use of cilta-cel as early as second line in the treatment course. In CARTITUDE-4 (as-treated population), 80.0% of patients with standard-risk cytogenetics were progression free and off treatment at 2.5 years. In patients with standard-risk disease who achieved MRD-negative CR at 1 year, this rate increased to 100.0%. The low rate of progression events in cilta-cel-treated patients with standard-risk cytogenetics shows the profound benefit of a single cilta-cel infusion in this population.
Blood board: A virtual forum for classical hematology education and care improvement
Andrade-Gonzalez, Xavier , Martin, Emma C. St. , Nwachukwu, Nneka , Pritzl, Stephanie , Ruan, Gordon , Shah, Deep , Smith, Caleb , Vijayvargiya, Pooja , Godby, Richard , Story, Charlotte McIlwaine , Marshall, Ariela L. , May, Jori E.

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 6420-6420

10.1182/blood-2025-6420 Get It

Abstract Introduction: The landscape of classical hematology has undergone substantial evolution over the last decade, marked by new diagnostic tools, nuanced therapeutic strategies, and an expanding understanding of underlying pathophysiology. This increasing complexity often presents unique diagnostic and therapeutic challenges. These challenges are further compounded by workforce shortages in classical hematology marked by educational gaps, geographic limitations, and difficulty accessing prompt specialty care. Unlike the well-established “Tumor Boards” in oncology, a comparable dedicated, widely accessible forum for classical hematology has largely been absent. This gap contributes to potential practice heterogeneity and isolation, especially across dissimilar care settings and geographic regions, impacting the consistent application of evidence-based practices and access to specialized expertise. To address this critical need, the “Blood Board” initiative was created to serve as an informal, virtual resource for discussing classical hematology topics and cases, fostering diverse perspectives, and collaborative problem-solving. Methods: The Blood Board was formally launched in April 2025, operating as a bi-monthly, hour-long virtual meeting conducted via non-recorded videoconferencing. The forum was designed with broad inclusivity in mind, welcoming all healthcare professionals involved in the care of adult patients with classical hematologic disorders, including trainees such as hematology/oncology fellows, academic and community-based hematologists, and any other interested providers. To date, dissemination of this initiative has been by word of mouth and e-mails containing a calendar invitation have been sent to anyone interested in participating (https://forms.gle/doyHNSx1SVFBJZmy8). To facilitate participation from various practice models and geographical locations, the virtual format was prioritized, eliminating barriers of travel and time commitment often associated with traditional in-person conferences. Participation is voluntary, encouraging an open and informal environment for de-identified case presentations, didactic discussions, and expert opinion sharing. Self-reported data on participant demographics (e.g., role, practice setting) and geographical representation have been collected to assess the initiative's reach and impact. Results: To date, sessions have consistently garnered engagement with a median of five participants in attendance at each session. There have been over 20 unique participants representing a broad spectrum of roles including both trainees and practicing hematologists/hematologist-oncologists and drawing from private practice, community-based hospitals, and academic medical centers. Over half of all participants were either in fellowship or within five years of completion of training. The virtual format has successfully overcome geographical limitations, attracting attendees from numerous states including Alabama, Florida, Georgia, Maryland, Minnesota, Missouri, Pennsylvania, South Dakota, and Wisconsin highlighting its broad appeal and potential for knowledge dissemination across a wide professional network. Conclusions: The Blood Board has demonstrated utility and met a previously unaddressed need. Sustained intellectual interest in Blood Board, coupled with a wide geographical and professional reach underscores a critical role for accessible, free, and multidisciplinary collaborative platforms in the evolving field of classical hematology. Similar to Tumor Boards, Blood Board promotes knowledge exchange and evidence-based care, garners expert support for challenging cases, and harmonizes clinical approaches, which we hope may ultimately improve patient care outcomes across diverse settings. Furthermore, this platform facilitates a national classical hematology community to support workforce development. Future goals include expanding dissemination efforts, measuring specific educational benefits, analyzing impacts on patient care, and increasing participant diversity, including recruitment of advanced practice providers and pharmacists.
Incidence and outcomes of Clostridioides difficile infection in BCMA and CD19 CAR-T cell therapy.
Shah, Raj, Tom, Fady El, Mahadevia, Himil, Vojjala, Nikhil, Kassem, Jad, Patel, Kalan, Shah, Raj, Tom, Fady El, Mahadevia, Himil, Vojjala, Nikhil, Kassem, Jad, Patel, Kalan

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 7678-7678

10.1182/blood-2025-7678 Get It

Abstract Background: Clostridioidesdifficile infection (CDI) represents a significant infectious complication in both Chimeric Antigen Receptor(CAR) T-cell therapy and hematopoietic stem cell transplant (HSCT) recipients. We sought to investigate the incidence and outcomesof CDI among various CAR-T therapy products. Methods: This retrospective study used the 2022 National Inpatient Sample Database to identify and include adult patients with a primary diagnosis of four hematologic malignancies (Non-Hodgkin Lymphoma (NHL), Multiple Myeloma (MM), Acute Lymphoblastic Leukemia (ALL), and Acute Myeloid Leukemia (AML). In this cohort, we isolated patients who developed CDI using ICD-10 codes. Subgroup analysis was performed based on the type of CAR-T cell therapy and HSCT recipients. Multivariate regression analysis was performed to identify independent risk factors for CDI and mortality. A p-value < 0.05 was considered statistically significant. Results: A total of 8,739 patients with CDI were identified among 507,559 patients with four hematologic malignancies, representing an overall incidence of 1.72%. Patients receiving CAR-T cell therapy (5% vs 2%, p<0.05), bone marrow transplant (BMT, 3% vs 2%, p<0.05), and those with a history of BMT (6% vs 2%, p<0.05) were at significantly higher risk for CDI. Among individual CAR-T products, the incidence was: for CD19-directed CAR-T, Brexu-cel 5%, Axi-cel 6%, Tisa-cel 5%, and Liso-cel 3%; for BCMA-directed CAR-T, Ide-cel 4% and Cilta-cel 5%. There was no significant difference in CDI rates between these individual CAR-T products. Among CAR-T recipients by cancer type, CDI incidence was NHL 5%, MM 4%, ALL 7%, and AML 5% (p=0.79). Multivariate regression identified history of HSCT (OR 2.11, 95% CI 1.09–4.08), cytokine release syndrome (OR 1.7; 1.26–2.52), protein-energy malnutrition (OR 2.08; 1.83–2.36), graft versus host disease (OR 2.52; 2.02–3.15), and female sex (OR 1.23; 1.10–1.38) as significant independent risk factors for CDI (all p<0.05). Overall mortality in those with CDI was 6% compared to 5% without, and mortality increased substantially to 36% in those requiring surgical intervention for CDI. Conclusion: In patients with hematologic malignancies, identifying risk factors and rates of CDI in CAR-T cell therapy is essential for prompt recognition and effective management. Future research on optimizing CDI screening protocol and prevention strategies can help reduce mortality and morbidity in this immunocompromised population.
Standardizing lines of treatment (LOT) in multiple myeloma: Real-world validation of an automated rule-based algorithm
Pérez, Patricia Alejandra Flores, Capdevila, Juan Pablo, Bórquez, Karla Mariana Castro, Bennion, Samuel, Hydren, Jay, Galbuchi, Giovanni, Jensen, Rachel, Barnes, Mason, Esparza, Jael Antonio Liñán, Quiroz, Felipe Flores, Ahlstrom, Jennifer, Auclair, Daniel, Banerjee, Rahul, Landgren, Ola, Coffey, David, Abdallah, Nadine, Shah, Urvi, Voorhees, Peter, Sborov, Douglas, Hultcrantz, Malin, Martinez, Jorge Arturo Hurtado, Pérez, Patricia Alejandra Flores, Capdevila, Juan Pablo, Bórquez, Karla Mariana Castro, Bennion, Samuel, Hydren, Jay, Galbuchi, Giovanni, Jensen, Rachel, Barnes, Mason, Esparza, Jael Antonio Liñán, Quiroz, Felipe Flores, Ahlstrom, Jennifer, Auclair, Daniel, Banerjee, Rahul, Landgren, Ola, Coffey, David, Abdallah, Nadine, Shah, Urvi, Voorhees, Peter, Sborov, Douglas, Hultcrantz, Malin, Martinez, Jorge Arturo Hurtado

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 8154-8154

10.1182/blood-2025-8154 Get It

Abstract Background Accurate reconstruction of electronic health record (EHR) treatment sequences is essential for leveraging real-world data (RWD) in clinical research and trial-eligibility platforms in multiple myeloma (MM). However, inconsistencies in RWD treatment documentation and the complexity of line-of-treatment (LOT) assignments in MM hinder reproducibility and limit comparisons against published trials. To address these limitations, we developed HEAL-MM, an automated rule-based algorithm that systematically parses structured medication data to calculate LOTs and segment treatment into standardized, clinically meaningful phases. The algorithm is designed to be interpretable, adaptable to evolving therapeutic frameworks, and compatible with widely adopted EHR data standards. Here, we report its real-world validation against expert-adjudicated treatment sequences to assess concordance, identify edge-case failure points, and support RWD integration. Methods A stratified cohort of 100 MM patients (9,136 structured treatment events) was curated from 114 unique healthcare systems compiled from the multi-institutional HealthTree Foundation harmonized registry. Cohort selection was randomized to ensure coverage across diagnostic eras (pre-2010, 2015–2020, 2022–2025) and treatment exposures, including CAR T-cell therapies, bispecific antibodies, and anti-CD38-based regimens. HEAL-MM sequenced MM regimens chronologically and applied predefined logic rules to identify LOT transitions, the initiation of a new therapeutic course based on drug changes, treatment gaps, and procedural anchors such as stem cell transplant or CAR T. Within each LOT, the algorithm segments and labels therapy into phases, clinically distinct intervals (e.g., induction and maintenance) using rule-based clinical logic. Outputs were benchmarked against expert-labeled adjudications. Concordance was evaluated using concordance index (C-index), stratified by patient, LOT depth and diagnostic era. Results: HEAL-MM demonstrated high concordance with expert-labeled treatment sequences: 0.94 for LOT identification, 0.98 for treatment phase segmentation, and 0.96 for phase label assignment. Achieving complete agreement with all expert annotations in 90% of patients for LOT assignment, 94% for the number of treatment phases identified, 77% for the specific labels applied to each phase, and 75% across all three dimensions simultaneously. Among discordant patients, the absolute difference in final LOT count was 0.5 ± 0.9. Performance was highest in early lines (LOTs 1–3; C-index: 0.97), with seven patients showing discrepancies at this stage. Concordance declined in later lines (LOT ≥4; C-index: 0.87), where 50% of the discordant cases (n=4) were attributable to misclassifications in earlier LOTs, such as medication restarts following >3-month gaps, demonstrating the compounding effect of early errors on longitudinal accuracy. Temporal stratification revealed improved accuracy in post-2020 cases (C-index: 0.94) compared to 2015–2020 cohorts (0.91), reflecting the increasing adoption of structured treatment standards and EHR data quality improvements. To assess HEAL-MM performance at clinically significant junctures, we analyzed treatment transitions that initiated a new LOT or marked a change in phase, achieving C-indices of 0.97 for LOT transitions, 0.97 for treatment phase shifts, and 0.94 for phase label assignment. Conclusions: HEAL-MM provides a validated, scalable solution for standardizing MM treatment structures in RWD environments, as it accurately detects the exact treatment entry of a new LOT 97% of the time. This rule-based framework enables reproducible LOT and phase assignment across heterogeneous EHR systems, supporting real-time cohort identification across institutions and EHR platforms. The algorithm's modular design allows for continuous integration of novel therapeutic categories and evolving treatment logic. While the algorithm maintained high fidelity overall, early-stage misclassifications consistent with increased heterogeneity and documentation ambiguity occasionally propagated downstream, underscoring the compounding effect of upstream errors in longitudinal reconstruction. With its generalizable structure and compatibility with industry-standard data models, HEAL-MM lays the foundation for structured treatment reconstruction in MM across RWD infrastructure and serves as a transferable blueprint for other hematologic malignancies.